Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.
Hover or tap a dot to see the filings behind that score.
Keenova Therapeutics plc (the “Company”) is unable to file, without unreasonable effort or expense, its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 (the “Form 10‑K”), with the Securities and Exchange Commission (the “SEC”) within the prescribed time period. The Company requires additional time to complete certain analyses and disclosures to be included in the Form 10-K due to the complexity of the accounting related to (i) the Company’s business combination with Endo, Inc. (“Endo”) completed in July 2025 (the “Business Combination”) and (ii) the Company’s separation of its generic pharmaceuticals and sterile injectables businesses into an independent, private company named Par Health, Inc. (“Par Health”) in November 2025 (the “Separation”), including updating purchase accounting and related valuations, the determination of discontinued operations presentation and related financial statement disclosures. The Company expects to file the Form 10-K within the extension period of 15 calendar days as provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended
NT 10-K, filed 2026-04-01 · acquisition or merger
Keenova Therapeutics plc (the “Company”) is unable to file, without unreasonable effort or expense, its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 (the “Form 10‑K”), with the Securities and Exchange Commission (the “SEC”) within the prescribed time period. The Company requires additional time to complete certain analyses and disclosures to be included in the Form 10-K due to the complexity of the accounting related to (i) the Company’s business combination with Endo, Inc. (“Endo”) completed in July 2025 (the “Business Combination”) and (ii) the Company’s separation of its generic pharmaceuticals and sterile injectables businesses into an independent, private company named Par Health, Inc. (“Par Health”) in November 2025 (the “Separation”), including updating purchase accounting and related valuations, the determination of discontinued operations presentation and related financial statement disclosures. The Company expects to file the Form 10-K within the extension period of 15 calendar days as provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended
2024-04-08auditor changed or resigned SEC →
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice